Med Sci (Paris)
Volume 40, Number 5, Mai 2024
Nos jeunes pousses ont du talent !
Page(s) 471 - 473
Section Partenariat médecine/sciences - Écoles doctorales - Masters
Published online 31 May 2024
  1. Lannoy N, Hermans C. Principles of genetic variations and molecular diseases: applications in hemophilia A. Critical Reviews in Oncology/Hematology 2016 ; 104 : 1–8. [CrossRef] [PubMed] [Google Scholar]
  2. Lorenzo JI, López A, Altisent C, et al. Incidence of factor VIII inhibitors in severe haemophilia: the importance of patient age. Br J Haematol 2001 ; 113 : 600–603. [CrossRef] [PubMed] [Google Scholar]
  3. McIntosh J, Lenting PJ, Rosales C, et al. Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant. Blood 2013 ; 121 : 3335–3344. [CrossRef] [PubMed] [Google Scholar]
  4. Louis Jeune V, Joergensen JA, Hajjar RJ, et al. Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy. Hum Gene Ther Methods 2013; 24 : 59–67. [CrossRef] [PubMed] [Google Scholar]
  5. Rangarajan S, Walsh L, Lester W, et al. AAV5-Factor VIII Gene Transfer in Severe Hemophilia A. N Engl J Med 2017 ; 377 : 2519–2530. [CrossRef] [PubMed] [Google Scholar]
  6. George LA, Monahan PE, Eyster ME, et al. Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A. N Engl J Med 2021; 385 : 1961–73. [CrossRef] [PubMed] [Google Scholar]
  7. Joo JH, Wang X, Singh S, et al. Intraosseous delivery of platelet-targeted factor VIII lentiviral vector in humanized NBSGW mice. Blood Adv 2022; 6 : 5556–69. [CrossRef] [PubMed] [Google Scholar]
  8. Nevill TJ, Barnett MJ, Klingemann HG, et al. Regimen-related toxicity of a busulfan-cyclophosphamide conditioning regimen in 70 patients undergoing allogeneic bone marrow transplantation. J Clin Oncol 1991 ; 9 : 1224–1232. [CrossRef] [PubMed] [Google Scholar]
  9. Hacein-Bey-Abina S, Garrigue A, Wang GP, et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 2008 ; 118 : 3132–3142. [CrossRef] [PubMed] [Google Scholar]
  10. Braun CJ, Boztug K, Paruzynski A, et al. Gene therapy for Wiskott-Aldrich syndrome–long-term efficacy and genotoxicity. Sci Transl Med 2014; 6 : 227ra33. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.